Schizophrenia (SCZ) and bipolar disorder (BD) are highly heritable disorders that share a significant proportion of common risk variation. Understanding the genetic factors underlying the specific symptoms of these disorders will be crucial for improving diagnosis, intervention and treatment. In case-control data consisting of 53,555 cases (20,129 BD, 33, 426 SCZ) and 54,065 controls, we identified 114 genome-wide significant loci (GWS) when comparing all cases to controls, of which 41 represented novel findings. Two genome-wide significant loci were identified when comparing SCZ to BD and a third was found when directly incorporating functional information. Regional joint association identified a genomic region of overlapping association in BD and SCZ with disease-independent causal variants indicating a fourth region contributing to differences between these disorders. Regional SNP-heritability analyses demonstrated that the estimated heritability of BD based on the SCZ GWS regions was significantly higher than that based on the average genomic region (91 regions, p = 1.2x10 -6 ) while the inverse was not significant (19 regions, p=0.89). Using our BD and SCZ GWAS we calculated polygenic risk scores and identified several significant correlations with: 1) SCZ subphenotypes: negative symptoms (SCZ, p=3.6x10 -6 ) and manic symptoms (BD, p=2x10 -5 ), 2) BD subphenotypes: psychotic features (SCZ p=1.2x10 -10 , BD p=5.3x10 -5 ) and age of onset ). Finally, we show that psychotic features in BD has significant SNP-heritability (h 2 snp =0.15, SE=0.06), and a significant genetic correlation with SCZ (r g =0.34) in addition there is a significant sign test result between SCZ GWAS and a GWAS of BD cases contrasting those with and without psychotic features (p=0.0038, one-side binomial test). For the first time, we have identified specific loci pointing to a potential role of 4 genes (DARS2, ARFGEF2, DCAKD and GATAD2A) that distinguish between BD and SCZ, providing an opportunity to understand the biology contributing to clinical differences of these disorders. Our results provide the best evidence so far of genomic components distinguishing between BD and SCZ that contribute directly to specific symptom dimensions.
Abstract
Schizophrenia (SCZ) and bipolar disorder (BD) are highly heritable disorders that share a significant proportion of common risk variation. Understanding the genetic factors underlying the specific symptoms of these disorders will be crucial for improving diagnosis, intervention and treatment. In case-control data consisting of 53,555 cases (20, 129 BD, 33, 426 SCZ) and 54,065 controls, we identified 114 genome-wide significant loci (GWS) when comparing all cases to controls, of which 41 represented novel findings. Two genome-wide significant loci were identified when comparing SCZ to BD and a third was found when directly incorporating functional information. Regional joint association identified a genomic region of overlapping association in BD and SCZ with disease-independent causal variants indicating a fourth region contributing to differences between these disorders. Regional SNP-heritability analyses demonstrated that the estimated heritability of BD based on the SCZ GWS regions was significantly higher than that based on the average genomic region (91 regions, p = 1.2x10 -6 ) while the inverse was not significant (19 regions, p=0.89 ). Using our BD and SCZ GWAS we calculated polygenic risk scores and identified several significant correlations with: 1) SCZ subphenotypes: negative symptoms (SCZ, p=3.6x10 -6 ) and manic symptoms (BD, p=2x10 -5 ), 2) BD subphenotypes: psychotic features (SCZ p=1.2x10 -10 , BD p=5.3x10 -5 ) and age of onset (SCZ p=7.9x10 -4 ). Finally, we show that psychotic features in BD has significant SNP-heritability (h 2 snp =0.15, SE=0.06), and a significant genetic correlation with SCZ (r g =0. 34 ) in addition there is a significant sign test result between SCZ GWAS and a GWAS of BD cases contrasting those with and without psychotic features (p=0.0038, one-side binomial test). For the first time, we have identified specific loci pointing to a potential role of 4 genes (DARS2, ARFGEF2, DCAKD and GATAD2A) that distinguish between BD and SCZ, providing an opportunity to understand the biology contributing to clinical differences of these disorders. Our results provide the best evidence so far of genomic components distinguishing between BD and SCZ that contribute directly to specific symptom dimensions.
Introduction
Bipolar disorder (BD) and schizophrenia (SCZ) are severe psychiatric disorders and among the leading causes of disability worldwide 1 . Both disorders have significant genetic components with heritability estimates ranging from 60-80% 2 . A genetic-epidemiological genetic study demonstrated a substantial overlap between these two disorders with a genetic correlation from common variation near 0.6-0.7 and high relative risks (RR) among relatives of both BD and SCZ patients (RRs for parent/offspring: BD/BD: 6.4, BD/SCZ: 2.4; SCZ/BD: 5.2, SCZ/SCZ: 9.9) 3 .
Despite shared genetics and symptomology, the current diagnostic systems 4,5 represent BD and SCZ as distinct categorical entities differentiated on the basis of their clinical presentation, with BD characterized by predominant mood symptoms, mood-congruent delusions and an episodic disease course and SCZ considered a prototypical psychotic disorder. Further, premorbid cognitive impairment and reduced intelligence are more frequent and severe in SCZ than BD 6 .
The genetic contributors to these phenotypic distinctions have yet to be elucidated and could aid in understanding the underlying biology of their unique clinical presentation.
While the shared genetic component is large, studies to date have identified key genetic architecture differences between these two disorders. A polygenic risk score created from a case only SCZ vs BD genome-wide association study (GWAS) significantly correlated with SCZ vs BD diagnosis in an independent sample 7 , providing evidence that differences between the disorders also have a genetic basis. An enrichment of rare, moderate to highly penetrant copy number variants (CNVs) and de novo CNVs are seen in SCZ patients [8] [9] [10] [11] [12] , while, the involvement of CNVs in BD is much less clear 13 . Although the role of de novo single nucleotide variants in BD and SCZ has been investigated in only a handful of studies so far, enrichment in pathways associated with the postsynaptic density has been reported for SCZ, but not BD 14, 15 . Identifying disorder-specific variants or quantifying the contribution of variation to specific symptom
dimensions remains an open question. For example, previous work by this group has demonstrated that SCZ patients with greater manic symptoms had higher polygenic risk for BD 7 .
Here, we utilize the largest collection of genotyped samples of BD and SCZ along with 28 subphenotypes to assess variants and genomic regions that contribute differentially to the disorders and to specific symptoms dimensions or subphenotypes within them.
Methods

Sample Description
SCZ samples are those analyzed previously 16 For analyses directly comparing BD and SCZ, we matched cases from both phenotypes on genotyping platform and ancestry, resulting in 15,270 BD cases versus 23,585 SCZ cases. In other words, we were able to match 76% of BD cases and 71% of SCZ cases.
Sub-phenotype description
BD sub-phenotypes were collected by each study site using a combination of diagnostic instruments, case records and participant interviews. Ascertainment details for each study site are described in the supplementary data of the PGC Bipolar Working Group paper (Stahl et al.
submitted). The selection of phenotypes for collection by this group was determined by literature searches in order to determine phenotypes with prior evidence for heritability. It was further refined dependent on the availability of phenotype data across a range of study sites and the consistency by which the phenotypes were defined. Schizophrenia subphenotypes are the same as described previously but in a larger proportion of patients 7 .
Quality Control, Imputation, Association Analysis and Polygenic Risk Scoring
Quality control and imputation were performed on each of the study cohort datasets (n=81), according to standards established by the Psychiatric Genomics Consortium (PGC were included in all association analyses (λ=1.45). Analytical steps were repeated for SCZ vs BD analysis.
We performed four main association analyses, i.e. (i) GWAS of BD and SCZ as a single combined case phenotype, as well as disorder-specific GWAS using independent control sets in (ii) BD cases vs BD controls and (iii) SCZ cases vs SCZ controls, and (iv) association analysis of SCZ cases vs BD cases. 20 We used SMR as a statistical fine-mapping tool applied to the SCZ vs BD GWAS results to identify loci with strong evidence of causality via gene expression. SMR analysis is limited to significant (FDR < 0.05) cis SNP-expression quantitative trait loci (eQTLs) with MAF > 0.01. eQTLs passing these thresholds were combined with GWAS results in the SMR test, with significance (p SMR ) reported at a Bonferroni-corrected threshold for each eQTL data set. The eQTL architecture may differ between genes. Through LD, many SNPs can generate significant associations with the same gene, but in some instances multiple SNPs may be independently associated with the expression of a gene. After identification of significant SNP-expression-trait association through the SMR test, a follow-up heterogeneity test aims to prioritize variants by excluding regions for which there is conservative evidence for multiple causal loci (p HET < 0.05).
Summary-data-based Mendelian Randomization (SMR)
SMR analyses were conducted using eQTL data from whole peripheral blood 21 , dorsolateral prefrontal cortex generated by the CommonMind Consortium 8 , and 11 brain sub-regions from the GTEx consortium 22 . Regions were considered to support a particular model when the posterior probability of the model was greater than 0.5.
Regional joint GWAS
Regional SNP-heritability estimation
We calculated local SNP-heritability independently for SCZ and BD using the Heritability Estimator from Summary Statistics (HESS) software 25 for each of the independent regions defined above. The sum of these regional estimates is the total SNP-heritability of the trait. Table 1 ). Two genomewide significant loci were identified, the most significant of which was rs56355601 located on chromosome 1 at position 173,811,455 within an intron of DARS2. The second most significant locus was a four base indel on chromosome 20 at position 47638976 in an intron of ARFGEF2.
For both variants, the minor allele frequency was higher in BD cases than SCZ cases and disease-specific GWAS showed opposite directions of effect. We sought to identify additional disease specific loci by incorporating expression information with association results to perform fine-mapping and identify novel variants [27] [28] [29] [30] . Here, we applied the summary-data-based Mendelian randomization (SMR) method 20 (see Methods) utilizing the cis-QTLs derived from peripheral blood 21 , human dorsolateral prefrontal cortex (DLPFC) 31 from the Common Mind Consortium and 11 brain regions from the GTEx consortium 22 . We identified one SNP-probe combination that surpassed the threshold for genome-wide significance in blood but was also the most significant finding in brain. We found that SNP rs4793172 in gene DCAKD is associated with SCZ vs BD analysis (p GWAS = 2.8x10 -6 ) and is an eQTL for probe ILMN 1811648 (p eQTL = 2.9x10 -168 ), resulting in p SMR = 4.1x10 -6 in blood (p eQTL = 2.9x10 -25 , p SMR = 2.0x10 -5 in DLFC, and p eQTL = 4.6x10 -15 , p SMR = 6.0x10 -5 in GTEx cerebellar hemisphere) (Supplementary Table 2 ,
Supplementary Figure 6 ) and shows no evidence of heterogeneity (p HET =0.66) which implies only a single causal variant in the region.
Regional joint association
We expanded our efforts to identify disorder specific genomic regions by jointly analyzing independent GWAS results from BD and SCZ 23 Figure 7) . The most significant variant in BD was rs111444407 (chr19:19358207, p = 8.67x10 -10 ) and for SCZ was rs2315283 (chr19:19480575, p=4.41x10 -7 ) . After conditioning on the most significant variant in the other disorder, the association signals of the most significant variant in BD and SCZ were largely unchanged (BD rs111444407 =1.3x10 -9 , SCZ rs2315283 p=6.7x10 -5 ). We further calculated the probability of each variant in the region being causal for both BD and SCZ 32 and found no correlation (r= -0.00016). The most significant variants had the highest posterior probability of being causal (SCZ: rs2315283, prob = 0.02, BD: rs111444407, prob = 0.16). Both variants most significantly regulate the expression of GATAD2A in brain 31 but in opposite directions (rs111444407 p eQTL = 6x10 -15 , beta = 0.105; rs2315283 p eQTL = 1.5x10 -28 , beta = -0.11).
Regional SNP-heritability estimation
Across the genome, regional SNP-heritabilities (h 2 snp ) were estimated separately for SCZ and BD 25 and were found to be moderately correlated (r=0.25). We next defined risk regions as those containing the most associated SNP for each GWS locus. In total, there were 101 SCZ risk regions from the 105 autosomal GWS loci reported previously 16 for both BD and SCZ comprising 33% of BD risk regions and 10% of SCZ risk regions. We further stratified regional h 2 snp by whether a region was a risk region in one disorder, none or both ( Figure 2 ). Since the discovery data for the regions overlapped with the data used for the heritability estimation, we expected within-disorder analyses to show significant results. In risk regions specific to SCZ (n=91) there was a significant increase in regional h 2 snp in SCZ, as expected (p = 1.1x10 -22 ), but also in BD (p = 1.2x10 -6 ). In risk regions specific to BD (n=19), significantly increased regional h 2 snp was observed in BD, as expected (p = 0.0007), but not in SCZ (p = 0.89). Risk regions shared by both disorders had significantly higher h 2 snp in both disorders, as expected (BD p = 5.3x10 -5 , SCZ p = 0.006), compared to non-risk regions.
However, we observed a significant increase in BD h 2 snp in shared risk regions compared to BD risk regions (BD p = 0.003) but not SCZ h 2 snp for shared risk regions compared to SCZ risk regions (p = 0.62). Using a less stringent p-value threshold for defining risk regions (p < 5x10 -6 ), thereby substantially increasing the number of regions, resulted in similar results ( Supplementary   Figure 8 ). Seven regions contributed to substantially higher h 2 snp in SCZ compared to BD but no region showed the inverse pattern. Of these regions, all but one was in the major histocompatibility region (MHC), the sole novel region was chr10:104380410-106695047 with regional h 2 snp = 0.0019 in SCZ and h 2 snp =0.00063 in BD.
Polygenic dissection of subphenotypes
Subphenotypes were collected for a subset of patients in both BD and SCZ (see Methods). For SCZ, we had clinical quantitative measurements of manic, depressive, positive and negative symptoms generated from factor analysis of multiple instruments as described previously 7 but in larger sample sizes (n=6908, 6907, 8259, 8355 respectively). For BD, 24 subphenotypes were collected among nearly 13,000 cases in distinct categories including comorbidities, clinical information such as rapid cycling and psychotic features as well as additional disease course data such as age of onset and number of hospitalizations. For each BD and SCZ patient, we calculated a polygenic risk score (PRS) using all SNPs, from each of the four main GWAS analyses (BD+SCZ, BD, SCZ and SCZvsBD). We then used regression analysis including principal components and site to assess the relationship between each subphenotype and the 4 PRS. We applied a significance cutoff of p < 0.0004 based on Bonferroni correction for 112 tests. In total, we identified 6 significant results after correction ( Figure 3 , Table 1 ). For BD PRS we see a significant positive correlation between PRS and manic symptoms in SCZ cases as seen previously 7 Supplementary Table 3 ).
For all 8 quantitative subphenotypes and 9 binary subphenotypes having at least 1,000 cases, we performed a GWAS within cases to calculate heritability and genetic correlation with BD and SCZ. Only two subphenotypes had significant h 2 snp estimates using LD-score regression 33 
Discussion
Here we present a genetic dissection of bipolar disorder and schizophrenia from over 100,000 genotyped subjects. As previously shown 34 , we found an extensive degree of genetic sharing between these two disorders. We identified 114 genome-wide significant loci contributing to both disorders of which 37 are novel to this analysis. Despite the high degree of sharing, we identified several loci that significantly differentiated between the two disorders, having opposite directions of effect, and polygenic components that significantly correlated from one disorder to symptoms of the other.
Two GWS loci were identified from the case only SCZ versus BD analysis providing opportunities to inform the underlying biological distinctions between BD and SCZ. The most significant locus is in DARS2 (coding for the mitochondrial Aspartate-tRNA ligase) which is highly expressed in the brain and significantly regulated by the most significant SNP rs56355601 (p eQTL =2.5x10 -11 ). Homozygous mutations in DARS2 are responsible for leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL), which was characterized by neurological symptoms such as psychomotor developmental delay, cerebellar ataxia and delayed mental development 35 . Interestingly, based on methylation analysis from the prefrontal cortex of stress models (rats and monkeys) and from peripheral samples (in monkeys and human newborns), DARS2, among others, has been suggested as a potential molecular marker of early-life stress and vulnerability to psychiatric disorders 36 . The second most significant locus maps to ARFGEF2, which codes for ADP Ribosylation Factor Guanine Nucleotide Exchange Factor 2 (also known as BIG2), a protein involved in vesicular trafficking from the trans-Golgi network. Mutations in ARFGEF2 have been shown to underlie an autosomal recessive condition characterized by microcephaly and periventricular heterotopia, a disorder caused by abnormal neural proliferation and migration 37 . Although not genome-wide significant, the third most significant locus implicates ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator Like), which is a core component of the circadian clock. ARNTL has been previously hypothesized for relevance in bipolar disorder, 38 although human genetic evidence is limited 39 . Incorporating transcriptional data identified a third genome-wide significant finding in DCAKD. The gene codes for Dephospho-CoA Kinase Domain Containing, a member of the human postsynaptic density proteome from human neocortex 40 . In the mouse cortical synaptoproteome DCAKD has been found to be among the proteins with the highest changes between juvenile postnatal days and adult stage, which suggests a putative role in brain development 41, 42 .
We further assessed the contribution of regions of the genome to each disorder through joint regional association and regional heritability estimation. These results point to two additional loci that may contribute differentially to liability to BD and SCZ. The region on chr19 shows overlapping association peaks that are driven by independent causal variants for each disorder.
Both variants significantly regulate the same gene GATAD2A but in opposite directions.
GATAD2A is a transcriptional repressor, which is targeted by MBD2 and is involved in methylation-dependent gene silencing. The protein is part of the large NuRD (nucleosome remodeling and deacetylase) complex, for which also HDAC1/2 are essential components. NurD complex proteins have been associated to autism 43 . Their members, including GATAD2A, display preferential expression in fetal brain development 43 and in recent work has been implicated in SCZ through open chromatin 44 . Further, p66a (mouse GATAD2A) was recently shown to participate in memory preservation through long-lasting histone modification in hippocampal memory-activated neurons 45 . The region on chromosome 10 appears to be shared across both disorders; however, there are additional independent contributing variants to SCZ and not BD, indicating another region of interest, although biological interpretation remains unknown.
More broadly, SNP-heritability appears to be consistently shared across regions and chromosomes between these two disorders. Regions with GWS loci often explain higher proportions of heritability as expected. When looking at the effect on heritability of the presence of a GWS locus in the other disorder, we identified a significant increase in BD heritability for regions containing a GWS locus for SCZ but no significant increase in SCZ heritability in regions having a BD one. This result suggests a directionality to the genetic sharing of these disorders with a larger proportion of BD loci being specific to BD. However, we cannot exclude that the asymmetry of results may reflect less power of discovery for BD than SCZ. The degree to which power and subphenotypes contribute to this result requires further examination.
We have now identified multiple genomic signatures that correlate between one disorder and a clinical symptom in the other disorder, demonstrating that there are genetic components underlying particular symptom dimensions within these disorders. As previously shown, we find a significant positive correlation between PRS of BD and manic symptoms in SCZ. We also demonstrate that BD cases with psychotic features carry a significantly higher SCZ PRS than BD cases without psychotic features and this result is not driven by schizoaffective BD subtype.
Further, we show evidence that increased PRS is associated with more severe illness. This is true for BD with psychotic features having increased SCZ PRS, earlier onset BD having higher SCZ PRS and cases with higher BD+SCZ PRS having a larger number of hospitalizations. We demonstrated that psychotic features within BD is an independently heritable trait and that GWS loci for SCZ have a consistent direction of effect in psychotic features in BD, demonstrating the potential to study psychosis more directly to identify variants contributing to that symptom dimension. All in all, this work illustrates the utility of genetic data to dissect symptom heterogeneity among correlated disorders and suggests that further work could potentially aid in defining subgroups of patients for more personalized treatment. 
